drugset
Drugs / SJG-136
last change Jun 2014 re-read 3 minutes ago

SJG-136

also known as BN-2629 · NSC #694501 · SG2000 · SP-2001 · UP-2001

Small molecule

Developed for
cancer of unknown primary site · acute myeloid leukemia · acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) · acute myeloid leukemia with t(8;21)(q22;q22) translocation · acute promyelocytic leukemia · adult acute lymphoblastic leukemia · B-cell chronic lymphocytic leukemia
+6 more · blast phase chronic myelogenous leukemia, BCR-ABL1 positive · chronic lymphocytic leukemia/small lymphocytic lymphoma · fallopian tube carcinoma · malignant epithelial tumor of ovary · myelodysplastic syndrome · primary peritoneal carcinoma
Investigated by
National Cancer Institute (NCI) · Spirogen

Trials 5

today NCT02034227 · Ph 1/2 NCT01200797 · Ph 2 NCT00301769 · Ph 1 NCT00121290 · Ph 1 NCT00103220 · Ph 1
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT00301769 Dec 2005 → Feb 2009 B-cell chronic lymphocytic leukemia, acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22), acute myeloid leukemia with t(8;21)(q22;q22) translocation +4 National Cancer Institute (NCI) Terminated No outcome recorded
Phase 1 NCT00121290 Feb 2005 → Apr 2008 cancer of unknown primary site National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00103220 Nov 2004 → Feb 2007 cancer of unknown primary site National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT02034227 Apr 2012 → Jun 2014 acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma Spirogen Terminated No outcome recorded
Phase 21 trial
Phase 2 NCT01200797 Jul 2010 → Oct 2012 fallopian tube carcinoma, malignant epithelial tumor of ovary, primary peritoneal carcinoma National Cancer Institute (NCI) Terminated No outcome recorded Stop: Enrollment

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as SJG-136 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00121290 ↗
3

NCT00301769 ↗

NCT01200797 ↗

NCT00103220 ↗
Known as BN-2629 ChEMBL registry synonym — accepted as the source's own label CHEMBL16498 ↗
Known as NSC #694501 “A Phase I Study With SJG-136 (NSC #694501) in Patients With an Advanced Solid Tumor” NCT00103220 ↗
Known as SG2000 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02034227 ↗
Known as SP-2001 ChEMBL registry synonym — accepted as the source's own label CHEMBL16498 ↗
Known as UP-2001 ChEMBL registry synonym — accepted as the source's own label CHEMBL16498 ↗
Modality Other / unclassified “DNA minor groove binding agent” NCT02034227 ↗
Modality Small molecule — CHEMBL16498 ↗
Route Intravenous “Patients receive SJG-136 intravenously (IV) over 20 minutes on days 1, 8, and 15.” NCT00103220 ↗